Reports FY22 revenue $329.2M, consensus $327.42M. Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "In 2022, we made significant progress across the business heading into what we believe will be a pivotal year for Amicus. We delivered strong growth in Galafold, highlighted by the over 2,000 people around the world who are now on treatment. We set a strong foundation for the anticipated global launch of our second product. And finally, we streamlined our pipeline while continuing our judicious management of resources. In 2023, we remain laser focused on continuing to grow Galafold globally at double-digit rates, preparing for the expected approvals and launches of AT-GAA for Pompe disease in multiple major markets, and maintaining our financial discipline in order to achieve non-GAAP profitability in the second half of this year. These strategic priorities align with our mission to deliver innovative treatments that impart a meaningful difference in the lives of people living with rare diseases."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FOLD:
- Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
- Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
- Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
- Amicus reports ‘positive’ long-term data from Phase 3 study of AT-GAA
- Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
